EQUILLIUM, INC. Revenue
EQUILLIUM, INC. (EQ) reported Revenue of $41.09 million for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-25.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-03-25
- EQUILLIUM, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2024-12-31 was $4.39M, a 52.32% decline year-over-year.
- EQUILLIUM, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2024-09-30 was $12.16M, a 37.10% increase year-over-year.
- EQUILLIUM, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2024-06-30 was $13.85M, a 51.83% increase year-over-year.
- EQUILLIUM, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2024-03-31 was $10.69M, a 20.39% increase year-over-year.
- EQUILLIUM, INC. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $41.09M, a 13.89% increase from fiscal 2023.
- EQUILLIUM, INC. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $36.08M, a 128.97% increase from fiscal 2022.
- EQUILLIUM, INC. revenue from contract with customer, excluding assessed tax for fiscal 2022 was $15.76M.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2024-12-31 | $4.39M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $16.55M derived: sum of 2 quarters · filed 2026-03-25 | $30.41M derived: sum of 3 quarters · filed 2026-03-25 | $41.09M 10-K · filed 2026-03-25 |
| 2024-09-30 | $12.16M 10-Q · filed 2025-11-13 | $26.01M derived: sum of 2 quarters · filed 2025-11-13 | $36.70M 10-Q · filed 2025-11-13 | $45.91M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $13.85M 10-Q · filed 2025-08-14 | $24.54M 10-Q · filed 2025-08-14 | $33.75M derived: sum of 3 quarters · filed 2025-08-14 | $42.62M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $10.69M 10-Q · filed 2025-05-14 | $19.90M derived: sum of 2 quarters · filed 2025-05-14 | $28.77M derived: sum of 3 quarters · filed 2025-05-14 | $37.89M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $9.21M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $18.08M derived: sum of 2 quarters · filed 2025-03-27 | $27.20M derived: sum of 3 quarters · filed 2025-03-27 | $36.08M 10-K · filed 2025-03-27 |
| 2023-09-30 | $8.87M 10-Q · filed 2024-11-13 | $17.99M derived: sum of 2 quarters · filed 2024-11-13 | $26.87M 10-Q · filed 2024-11-13 | |
| 2023-06-30 | $9.12M 10-Q · filed 2024-08-08 | $18.00M 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | $8.88M 10-Q · filed 2024-05-09 | |||
| 2022-12-31 | $15.76M 10-K · filed 2024-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |